Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.44 |
| ▸ | TERT | O14746 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | DRD4 | P21917 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28164677 | 0.87 | SMN1; SMN2 (0.44) | SMN1; SMN2TERTALDH1A1KDM4EMAPT | |
| SCHEMBL21675522 | 0.85 | SMN1; SMN2 (0.42) | SMN1; SMN2ALDH1A1KDM4EHPGDLMNA | |
| SCHEMBL14621507 | 0.85 | HSD17B10 (0.45) | SMN1; SMN2TERTALDH1A1KDM4EHPGD | |
| SCHEMBL18327519 | 0.84 | SMN1; SMN2 (0.41) | SMN1; SMN2ALDH1A1KDM4EMAPTRAB9A | |
| SCHEMBL12991730 | 0.83 | SMN1; SMN2 (0.66) | SMN1; SMN2ALDH1A1KDM4ERAB9AKMT2A | |
| SCHEMBL12437051 | 0.83 | SMN1; SMN2 (0.50) | SMN1; SMN2TERTALDH1A1KDM4EMAPT | |
| SCHEMBL5464002 | 0.82 | SMN1; SMN2 (0.38) | SMN1; SMN2ALDH1A1MAPTRAB9A | |
| SCHEMBL13629954 | 0.82 | SMN1; SMN2 (0.44) | SMN1; SMN2TERTALDH1A1KDM4EMAPT | |
| SCHEMBL13629959 | 0.80 | SMN1; SMN2 (0.50) | SMN1; SMN2TERTALDH1A1KDM4EMAPT | |
| SCHEMBL12640327 | 0.80 | ALDH1A1 (0.47) | SMN1; SMN2ALDH1A1MAPTRAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023081809-A1 | TRANS-CYCLOOCTENE-MODIFIED BISPECIFIC ANTIBODIES | TAMBO, INC. (US) | 2023-05-11 | — | — | WO | disclosed |
| WO-2023077129-A1 | TETRAZINE CONJUGATES FOR IN VIVO TARGETED DELIVERY OF A PAYLOAD | TAMBO, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| WO-2017205309-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-11-30 | — | — | WO | disclosed |
| US-7622487-B2 | Piperidine derivative, process for producing the same, and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-24 | — | — | US | disclosed |
| US-7622487-B2 | Piperidine derivative, process for producing the same, and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-24 | — | — | US | disclosed |
| US-20090156572-A1 | Nitrogen-containing heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2009-06-18 | — | — | US | disclosed |
| US-20090156572-A1 | Nitrogen-containing heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2009-06-18 | — | — | US | disclosed |
| WO-2009072643-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-11 | — | — | WO | disclosed |
| EP-1790636-A1 | PIPERIDINE DERIVATIVES AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2007-05-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156572-A1 | Nitrogen-containing heterocyclic compound and use thereof | NTSR2, NTSR1, HNMT | SMN1; SMN2 1425/4885TERT 3784/4885ALDH1A1 2667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.